Literature DB >> 34014497

State of the art of robotic pancreatoduodenectomy.

Niccolò Napoli1, Emanuele F Kauffmann1, Fabio Vistoli1, Gabriella Amorese2, Ugo Boggi3.   

Abstract

Current evidence shows that robotic pancreatoduodenectomy (RPD) is feasible with a safety profile equivalent to either open pancreatoduodenectomy (OPD) or laparoscopic pancreatoduodenectomy (LPD). However, major intraoperative bleeding can occur and emergency conversion to OPD may be required. RPD reduces the risk of emergency conversion when compared to LPD. The learning curve of RPD ranges from 20 to 40 procedures, but proficiency is reached only after 250 operations. Once proficiency is achieved, the results of RPD may be superior to those of OPD. As for now, RPD is at least equivalent to OPD and LPD with respect to incidence and severity of POPF, incidence and severity of post-operative complications, and post-operative mortality. A minimal annual number of 20 procedures per center is recommended. In pancreatic cancer (versus OPD), RPD is associated with similar rates of R0 resections, but higher number of examined lymph nodes, lower blood loss, and lower need of blood transfusions. Multivariable analysis shows that RPD could improve patient survival. Data from selected centers show that vein resection and reconstruction is feasible during RPD, but at the price of high conversion rates and frequent use of small tangential resections. The true Achilles heel of RPD is higher operative costs that limit wider implementation of the procedure and accumulation of a large experience at most single centers. In conclusion, when proficiency is achieved, RPD may be superior to OPD with respect to CR-POPF and oncologic outcomes. Achievement of proficiency requires commitment, dedication, and truly high volumes.

Entities:  

Year:  2021        PMID: 34014497     DOI: 10.1007/s13304-021-01058-8

Source DB:  PubMed          Journal:  Updates Surg        ISSN: 2038-131X


  20 in total

1.  Trends in hospital volume and operative mortality for high-risk surgery.

Authors:  Jonathan F Finks; Nicholas H Osborne; John D Birkmeyer
Journal:  N Engl J Med       Date:  2011-06-02       Impact factor: 91.245

2.  THE RATIONALE OF RADICAL SURGERY FOR CANCER OF THE PANCREAS AND AMPULLARY REGION.

Authors:  A O Whipple
Journal:  Ann Surg       Date:  1941-10       Impact factor: 12.969

3.  Alessandro Codivilla and the first pancreatoduodenectomy.

Authors:  Thomas Schnelldorfer; Michael G Sarr
Journal:  Arch Surg       Date:  2009-12

Review 4.  The Miami International Evidence-based Guidelines on Minimally Invasive Pancreas Resection.

Authors:  Horacio J Asbun; Alma L Moekotte; Frederique L Vissers; Filipe Kunzler; Federica Cipriani; Adnan Alseidi; Michael I D'Angelica; Alberto Balduzzi; Claudio Bassi; Bergthor Björnsson; Ugo Boggi; Mark P Callery; Marco Del Chiaro; Felipe J Coimbra; Claudius Conrad; Andrew Cook; Alessandro Coppola; Christos Dervenis; Safi Dokmak; Barish H Edil; Bjørn Edwin; Pier C Giulianotti; Ho-Seong Han; Paul D Hansen; Nicky van der Heijde; Jony van Hilst; Caitlin A Hester; Melissa E Hogg; Nicolas Jarufe; D Rohan Jeyarajah; Tobias Keck; Song Cheol Kim; Igor E Khatkov; Norihiro Kokudo; David A Kooby; Maarten Korrel; Francisco J de Leon; Nuria Lluis; Sanne Lof; Marcel A Machado; Nicolas Demartines; John B Martinie; Nipun B Merchant; I Quintus Molenaar; Cassadie Moravek; Yi-Ping Mou; Masafumi Nakamura; William H Nealon; Chinnusamy Palanivelu; Patrick Pessaux; Henry A Pitt; Patricio M Polanco; John N Primrose; Arab Rawashdeh; Dominic E Sanford; Palanisamy Senthilnathan; Shailesh V Shrikhande; John A Stauffer; Kyoichi Takaori; Mark S Talamonti; Chung N Tang; Charles M Vollmer; Go Wakabayashi; R Matthew Walsh; Shin-E Wang; Michael J Zinner; Christopher L Wolfgang; Amer H Zureikat; Maurice J Zwart; Kevin C Conlon; Michael L Kendrick; Herbert J Zeh; Mohammad Abu Hilal; Marc G Besselink
Journal:  Ann Surg       Date:  2020-01       Impact factor: 12.969

5.  Robotic-Assisted Pancreatic Resections.

Authors:  Ugo Boggi; Niccolò Napoli; Francesca Costa; Emanuele F Kauffmann; Francesca Menonna; Sara Iacopi; Fabio Vistoli; Gabriella Amorese
Journal:  World J Surg       Date:  2016-10       Impact factor: 3.352

6.  Comment on "Operable Pancreatic Cancer: Are We in an Era of Individualized Neoadjuvant Therapy?"

Authors:  Jie Hua; Si Shi; Xianjun Yu
Journal:  Ann Surg       Date:  2019-12       Impact factor: 12.969

7.  Feasibility of robotic pancreaticoduodenectomy.

Authors:  U Boggi; S Signori; N De Lio; V G Perrone; F Vistoli; M Belluomini; C Cappelli; G Amorese; F Mosca
Journal:  Br J Surg       Date:  2013-06       Impact factor: 6.939

8.  Optimal Pancreatic Surgery: Are We Making Progress in North America?

Authors:  Joal D Beane; Jeffrey D Borrebach; Amer H Zureikat; E Molly Kilbane; Vanessa M Thompson; Henry A Pitt
Journal:  Ann Surg       Date:  2019-10-28       Impact factor: 12.969

9.  Risk of conversion to open surgery during robotic and laparoscopic pancreatoduodenectomy and effect on outcomes: international propensity score-matched comparison study.

Authors:  S Lof; F L Vissers; S Klompmaker; S Berti; U Boggi; A Coratti; S Dokmak; R Fara; S Festen; M D'Hondt; I Khatkov; D Lips; M Luyer; A Manzoni; E Rosso; O Saint-Marc; M G Besselink; M Abu Hilal
Journal:  Br J Surg       Date:  2021-01-27       Impact factor: 6.939

10.  Assessment of quality outcomes for robotic pancreaticoduodenectomy: identification of the learning curve.

Authors:  Brian A Boone; Mazen Zenati; Melissa E Hogg; Jennifer Steve; Arthur James Moser; David L Bartlett; Herbert J Zeh; Amer H Zureikat
Journal:  JAMA Surg       Date:  2015-05       Impact factor: 14.766

View more
  1 in total

1.  ASO Author Reflections: The Importance of the Mesopancreas Excision During Pancreatoduodenectomies.

Authors:  Marcel Autran Machado; Fabio Makdissi
Journal:  Ann Surg Oncol       Date:  2021-08-04       Impact factor: 5.344

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.